Safety and efficay of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients

Pakistan Journal of Medical Sciences

Volumn 22, Issue 4, 2006, Pages 385-390

  Jibran, Rushd ^a   Suliman, M Imran ^b   Qureshi, Fayyaz ^b   Ahmed, Masood ^b  

^a PUNJAB INSTITUTE OF CARDIOLOGY   (Pakistan)

^b Women Medical College Pakistan   (Pakistan)

Author keywords

Glibenclamide; Glycosylated haemoglbin; HbA1c; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; REPAGLINIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAKISTAN; PATIENT COMPLIANCE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT CHANGE;

EID: 33845394293     PISSN: 1682024X     EISSN: 1682024X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC. Diabetes-enhanced inflammation and apoptosis-impact on periodontal pathology. J Dent Res 2006; 85(1): 15-21.
2. Sacks DB, McDonald JM. The pathogenesis of type 2 diabetes mellitus. A polygenic disease. Am J Clin Path 1996; 105: 149-56.
3. LeRoith D, Smith DO. Monitoring glycemic control: the cornerstone of diabetes care. Clin Ther 2005;27(10): 1489-99.
4. Zargar A, Basit A, Mahtab H. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan. J Indian Med Assoc 2005; 103(8): 444-6.
5. Kirchheiner J, Roots I, Golammer M, Rosen Kranz B, Brockmoller J. Effect of genetic polymorphism in cytochrome P450(CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs; clinical relevance. Clin Pharmacokinet 2005; 44 (12): 1209-225.
6. Mooridian AD. Drug therapy of non-insulin dependent diabetes mellitus in the elderly. Drugs 1996; 51:931-41.
7. Jennings AM, Wilson RM, Ward JD.symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabet Care 1989; 12:203-8.
8. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepride versus glibenclamide. Diabetes Metab Res Rev 2001; 17(6): 467-73.
9. Greco D, Angileri G. Drug-induced severe hypoglycemia in type 2 diabetic patients aged 80 years or older. Diabetes Nutr Metab 2004;17(1):23-6.
10. Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepride-versus glibenclamide-induced hypoglycemia. Eur J Clin Pharmacol 2003;59(2): 91-7.
11. Fuhlendroff J, Rossman P, Koyodo H. Stimulation of insulin release by repaglinide and glibenclamide involved both common and distinct process. Diabetes 1998; 47:345-51.
12. Rizzo Mr, Barbieri M, Grella R, Passariello N, Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepride: data from medtest study. Diabetes Matab 2005; 31(3pt1): 255-60.
13. Manzella D, Garella R, Abbatecola Am, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetic Care 2005; 28(2):366-71.
14. Damsbo P, Clauson P, Marbury C, Winfeild K. A double blind randomized comparison of meal related glycemic control by repaglinide and glyburuide in well controlled type 2 diabetic patients. Diabetic Care 1999; 22:789-94.
15. Goldberg RB, Einhorn D, Lucas CP. A randomized placebo controlled trial of repaglinide in the treatment of type 2 diabetes. Diabet Care 1998;21:1897-903.
16. th science session of the ADA, Boston, MA. 1997.
17. Owens DR. Repaglinide-prandial glucose relatorr: a new class of oral antidiabetic drugs. Diabet Med 1998; 15suppl.4: S28-36.
18. Jovanovich L, Dailey G, Huang WC. Repaglinide-in type 2 diabetes: a 24 week, fixed dose efficacy and safety. J Clinpharmacol 2000; 40(1):49-57.
19. Moses R, Slobodniuuk R, Boyages S, Kidson W. effects of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22(1):119-24.
20. Landgraf R, Billo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treate with sulphonylurea. Eur J Clin Pharmacol 1999; 55(3): 165-71.